MedTrace Logo

Heavy Light Chain in Chronic Lymphocytic Leukemia

NCT02377869 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2015-03-04

No results posted yet for this study

Summary

Recently, a novel assay for detecting heavy/light chain (HLC) ratios has been reported which enables improvement in paraprotein detection and monitoring in multiple myeloma and other plasma-cell dyscrasias.

The prognostic and biological role of the HLC assay has as yet not been studied in CLL.

Aims of the proposed study:

1. To quantify and analyze the prognostic significance of HLC ratios in the serum of CLL patients. (In addition to FLC)
2. To study the different patterns of Immunoglobulin's subclass antibodies in the serum of patients with CLL and compare them to those of to healthy volunteers.
3. To perform a sub-analysis in patients with CLL who have autoimmune phenomenon (AIHA and ITP)

Conditions

Interventions

OTHER

No intervantion

Sponsors & Collaborators

  • Rambam Health Care Campus

    collaborator OTHER

  • Laniado Hospital

    collaborator OTHER

  • Meir Medical Center

    collaborator OTHER

  • Rabin Medical Center

    collaborator OTHER

  • Kaplan Medical Center

    collaborator OTHER

  • Shaare Zedek Medical Center

    collaborator OTHER

  • Hadassah Medical Organization

    collaborator OTHER

  • HaEmek Medical Center, Israel

    collaborator OTHER

  • Western Galilee Hospital-Nahariya

    collaborator OTHER_GOV

  • Tel-Aviv Sourasky Medical Center

    collaborator OTHER_GOV

  • Assaf-Harofeh Medical Center

    collaborator OTHER_GOV

  • Bnai Zion Medical Center

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-01-31
Completion
2020-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02377869 on ClinicalTrials.gov